Discontinued ProductUnfortunately M-6434 (Cat. No. 0461) has been withdrawn from sale for commercial reasons.
An α1-agonist; a potent orally active hypertensive.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the products' biological activity.
Dabasaki et al (1992) Antihypotensive effects of M6434, an orally active alpha-1-adrenoceptor agonist in rats. Jpn.J.Pharmacol. 59 145 PMID: 1279249
Ohnish (1981) Pharmacological properties of 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole (M6434). Arzneimittelforschung 9 1425 PMID: 7197948
Tsuchid (1986) Effects of midodrine on experimentally-induced postural hypotension in dogs. Arzneimittelforschung 12 1748 PMID: 2436631
View Related Products by Product Action
Keywords: M-6434, supplier, An, a1-agonist;, a, potent, orally, active, hypertensive., Adrenergic, Alpha-1, Receptors, Adrenergic, Alpha-1, Receptors, Tocris Bioscience
Citations for M-6434
Citations are publications that use Tocris products.
Currently there are no citations for M-6434.
Reviews for M-6434
There are currently no reviews for this product. Be the first to review M-6434 and earn rewards!
Have you used M-6434?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.